海利生物
(603718)
| 流通市值：55.45亿 | | | 总市值：56.65亿 |
| 流通股本：6.44亿 | | | 总股本：6.58亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 70,304,397.74 | 240,722,981.59 | 194,603,133.9 | 118,892,260.05 |
| 营业收入 | 70,304,397.74 | 240,722,981.59 | 194,603,133.9 | 118,892,260.05 |
| 二、营业总成本 | 79,483,781.34 | 247,650,829.86 | 181,325,947.83 | 113,751,155.23 |
| 营业成本 | 39,553,800.94 | 117,004,710.95 | 95,639,368.06 | 51,924,379.06 |
| 税金及附加 | 790,907.96 | 3,146,351.4 | 2,424,731.86 | 1,543,540.52 |
| 销售费用 | 11,428,246.56 | 40,831,894.06 | 36,608,576.44 | 29,219,361.37 |
| 管理费用 | 21,100,810.08 | 58,942,170.49 | 26,481,179.39 | 17,521,721.83 |
| 研发费用 | 5,495,990.24 | 24,971,937.68 | 18,474,271.48 | 12,551,614.88 |
| 财务费用 | 1,114,025.56 | 2,753,765.28 | 1,697,820.6 | 990,537.57 |
| 其中:利息费用 | 1,343,984.59 | 5,389,081.95 | 3,359,563.76 | 1,882,422.63 |
| 其中:利息收入 | 236,226.73 | 2,677,282.65 | -1,681,114.16 | -898,508.33 |
| 加:公允价值变动收益 | 1,443,832.22 | -16,517,666.02 | 839,783.44 | 991,202.78 |
| 加:投资收益 | 857,854.31 | 73,140,499.3 | 57,647,724.44 | 67,655,060.24 |
| 资产处置收益 | - | 606,062.98 | 720,456.01 | 709,537.03 |
| 资产减值损失(新) | - | -3,297,108.44 | 1,522,044.12 | 1,522,044.12 |
| 信用减值损失(新) | 706,834.99 | -1,030,209.43 | -5,987,115.37 | -466,247.42 |
| 其他收益 | 657,675.24 | 9,196,896.81 | 8,528,436.48 | 7,991,532.25 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | -5,513,186.84 | 55,170,626.93 | 76,548,515.19 | 83,544,233.82 |
| 加:营业外收入 | 2,894.51 | 948,454.3 | 1,334,456.53 | 994,770.18 |
| 减:营业外支出 | 15,700.01 | 96,601.4 | 53,476.84 | 3,538.75 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | -5,525,992.34 | 56,022,479.83 | 77,829,494.88 | 84,535,465.25 |
| 减:所得税费用 | -1,164,889.12 | 6,008,711.66 | 12,760,895.56 | 10,912,891.14 |
| 六、净利润 | -4,361,103.22 | 50,013,768.17 | 65,068,599.32 | 73,622,574.11 |
| 持续经营净利润 | -4,361,103.22 | 50,013,768.17 | 65,068,599.32 | 73,622,574.11 |
| 归属于母公司股东的净利润 | -3,719,366.81 | 62,870,202.71 | 74,698,546.73 | 81,738,413.19 |
| 少数股东损益 | -641,736.41 | -12,856,434.54 | -9,629,947.41 | -8,115,839.08 |
| (一)基本每股收益 | -0.01 | 0.1 | 0.12 | - |
| (二)稀释每股收益 | -0.01 | 0.1 | 0.12 | - |
| 八、其他综合收益 | -8,270,656.09 | 13,001,673.01 | 7,804,209.3 | 14,094,135.63 |
| 归属于母公司股东的其他综合收益 | -8,270,656.09 | 13,001,673.01 | 7,804,209.3 | 14,094,135.63 |
| 九、综合收益总额 | -12,631,759.31 | 63,015,441.18 | 72,872,808.62 | 87,716,709.74 |
| 归属于母公司股东的综合收益总额 | -11,990,022.9 | 75,871,875.72 | 82,502,756.03 | 95,832,548.82 |
| 归属于少数股东的综合收益总额 | -641,736.42 | -12,856,434.54 | -9,629,947.41 | -8,115,839.08 |
| 公告日期 | 2024-04-30 | 2024-04-30 | 2023-10-31 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |